Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2008 | 3 | 3 | 341-345

Article title

Assessment of chemotherapy-induced anemia in children with cancer


Title variants

Languages of publication



Anemia is a common cause of co-morbidity in children with cancer. We reviewed a series of 124 children with non-metastatic cancer to assess the relationship between chemotherapy intensity, severe anemia, and frequency of transfusion. In more than 60% of children who received intensive chemotherapy, transfusions were prescribed compared to 38% and 21% of children treated with standard and mild chemotherapy, respectively. In conclusion, our data suggest that the intensity and duration of chemotherapy constitute important factors in determining the onset of anemia.










Physical description


1 - 9 - 2008
10 - 7 - 2008


  • Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy
  • Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy
  • Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy
  • Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy
  • Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy
  • Division of Paediatric Oncology, Catholic University, 00168, Roma, Italy


  • [1] Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H., Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin, Cancer, 1994, 73(10), 2535–42 http://dx.doi.org/10.1002/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5[Crossref]
  • [2] Corazza F., Beguin Y., Bergmann P., Andre M., Ferster A., Devalck C., Fondu P., Buyse M., Sariban E., Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production, Blood, 1998, 92(5),1793–8 [PubMed]
  • [3] Lai J.S., Cella D., Kupst M.J., Holm S., Kelly M.E., Bode R.K., Goldman S., Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F), J. Pediatr. Hematol. Oncol., 2007, 29(7), 471–9 http://dx.doi.org/10.1097/MPH.0b013e318095057a[WoS][Crossref]
  • [4] Jelkmann W., Developments in the therapeutic use of erythropoiesis stimulating agents, Br. J. Haematol., 2008, 141(3), 287–97 [PubMed]
  • [5] Dainiak N., Kulkarni V., Howard D., Kalmanti M., Dewey M.C., Hoffman R., Mechanisms of abnormal erythropoiesis in malignancy, Cancer, 1983, 51(6), 1101–6 http://dx.doi.org/10.1002/1097-0142(19830315)51:6<1101::AID-CNCR2820510622>3.0.CO;2-G[Crossref]
  • [6] Ludwig H., Fritz E., Anemia in cancer patients, Semin. Oncol. 1998, 25(3 Suppl 7), 2–6
  • [7] Ludwig H., Epoetin in cancer-related anaemia, Nephrol. Dial. Transplant., 1999, 14(S2), 85–92 http://dx.doi.org/10.1093/ndt/14.suppl_2.85[Crossref]
  • [8] Mercadante S., Gebbia V., Marrazzo A., Filosto S., Anaemia in cancer: pathophysiology and treatment, Cancer Treat. Rev., 2000, 26(4), 303–11 http://dx.doi.org/10.1053/ctrv.2000.0181[Crossref]
  • [9] Shankar A.G., The role of recombinant erythropoietin in childhood cancer, Oncologist,. 2008, 13(2),157–66 http://dx.doi.org/10.1634/theoncologist.2007-0126[Crossref][WoS]
  • [10] Means R.T. Jr, Krantz S.B., Progress in understanding the pathogenesis of the anemia of chronic disease, Blood, 1992, 80(7),1639–47
  • [11] Groopman J.E., Itri L.M., Chemotherapy-induced anemia in adults: incidence and treatment, J. Natl. Cancer Inst., 1999, 91(19), 1616–34. Erratum in: J. Natl. Cancer Inst., 2000, 92(6), 497 http://dx.doi.org/10.1093/jnci/91.19.1616[Crossref]
  • [12] Ruggiero A., Riccardi R., Interventions for anemia in pediatric cancer patients, Med. Pediatr. Oncol., 2002,39(4),451–4 http://dx.doi.org/10.1002/mpo.10184[Crossref]
  • [13] Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L., Decreased erythropoietin response in patients with the anemia of cancer, N. Engl. J. Med., 1990, 322(24), 1689–92 [Crossref]
  • [14] Adamson J.W., Ludwig H., Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer, Oncology, 1999, 56(1), 46–53 http://dx.doi.org/10.1159/000011929[Crossref]
  • [15] Schapira L., Antin J.H., Ransil B.J., Antman K.H., Eder J.P., McGarigle C.J., Goldberg M.A., Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy, Blood, 1990, 76(11), 2354–9
  • [16] Marc-Berad P., Blay J.K., Schell M., Buclon M., Demaret C., Ray-Coquard I., Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients, J. Clin. Oncol., 2003, 21, 4235–9 http://dx.doi.org/10.1200/JCO.2003.09.121[Crossref]
  • [17] Cascinu S., Fedeli A., Luzi Fedeli S., Catalano G., Cisplatin-associated anemia treated with subcutaneous erythropoietin. A pilot study, Br. J. Cancer, 1993, 67, 156–58 [Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.